
Description:

Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from self-monitoring blood glucose devices (SMBG). SMBG devices are cheaper and easy to use and have an less stringent approval process from authorities like FDA. SMBG has more number of players and larger market share. However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. CGM system market has seen good growth rates in past three years. Medtronic and Dexcom have introduced new systems which have witnessed lower frequency of errors. The MARD value for new sensors has decreased, new devices need lesser calibrations per day and most of the devices are approved for paediatric use. This has led to 50-60 percent jump in the revenues of some manufacturers.

Contents:
TABLE OF CONTENTS
CHAP 1. EXECUTIVE SUMMARY
CHAP 2. MARKET OVERVIEW
  2.1. WHAT IS CGMS?
  2.2. VALUE CHAIN ANALYSIS OF THE ROLE OF SUPPLIER, MANUFACTURER AND END USER IN THE CGM MARKET
  2.2.1. SUPPLIERS HELPING THE FINANCIALLY WEAK PLAYERS
  2.2.2. MANUFACTURERS FACING REGULATIONS AND OPERATIONAL COST ISSUES
  2.2.3. PEDIATRICS AND HOSPITALS WILL LEAD THE FUTURE MARKET GROWTH
  2.3. KEY BUYING CRITERIA
  2.3.1. CONVENIENCE FACTOR
  2.3.2. PRICE THE KEY CONCERN
  2.3.3. ACCURACY
  2.4. GAP ANALYSIS: UNREALISTIC GAP BETWEEN THE PROMISED PRODUCT AND DELIVERED PRODUCT
  2.5. STRATEGIC RECOMMENDATION
  2.5.1. COLLABORATION OF THE TWO MAIN MANUFACTURERS
  2.5.2. DEVELOPMENT OF LONG RUN SENSORS
  2.5.3. DEVELOPMENT OF ARTIFICIAL PANCREAS
  2.5.4. FOCUS ON DEVELOPING ASIAN MARKETS
  2.5.5. PARTNERSHIPS AND COLLABORATION – THE WINNING STRATEGIES
  2.5.6. INNOVATION THE ENTRY STRATEGY FOR NEW ENTRANTS
CHAP 3. MARKET DETERMINANTS
  3.1. MARKET MOTIVATORS CGMS MARKET
  3.1.1. DIABETES POPULATION RISE CAN LEAD TO LARGER MARKET OPPORTUNITY
  3.1.2. RISE IN THE GLOBAL HEALTH EXPENDITURE AND EMERGING ASIAN MARKET
  3.1.3. INCREASED R&D FUNDING FOR FASTER APPROVALS AND DEVELOPMENT OF ARTIFICIAL PANCREAS
  3.1.4. INSULIN PUMP MANUFACTURERS WILLING TO INTEGRATE CGM AND INSULIN PUMP TECHNOLOGY
  3.1.5. PRIVATE INSURERS HELPING DIABETIC PATIENTS TO AFFORD CGM SYSTEMS
  3.1.6. NEW TECHNOLOGY CAN BRING DOWN PRICES
  3.2. RESTRAINTS
  3.2.1. GOVERNMENT REGULATIONS DELAYING THE PROCESSES
  3.2.2. ESTABLISHED SMBG MANUFACTURERS RESTRAINING THE CGM GROWTH
3.2.3. POOR ACCESS TO THE HEALTH CARE SERVICES IN DEVELOPING MARKETS
3.3. OPPORTUNITIES
3.3.1. GROWING DIABETIC POPULATION
3.3.2. EMERGENCE OF NEW SEGMENT: PEDIATRICS
3.3.3. CASE STUDY ON PEDIATRICS USE
3.3.4. DEVELOPMENT OF ARTIFICIAL PANCREAS
3.4. CHALLENGES IN CGMS MARKET
3.4.1. HIGH PRICE
3.4.2. UNMET DIABETIC NEEDS
3.4.3. NO GOVERNMENT AID MAKES IT DIFFICULT FOR THE CONSUMER
CHAP 4. SECTOR ANALYSIS: DIABETES CARE
CHAP 5. CGM MARKET BY DEVICES
5.1. LONG LASTING SENSORS THE NEED FOR CGM MARKET GROWTH
5.1.1. FACTORS INFLUENCING CGM SENSOR DEVELOPMENT
5.2. TRANSMITTERS AND RECEIVERS- THE STANDALONE SYSTEM
5.2.1. PRICE THE MAJOR RESTRAINT FOR T&R
5.3. INSULIN PUMPS HOLD THE FUTURE
5.3.1. INNOVATION AND COLLABORATION THE MAINSTAY FOR INSULIN PUMPS
CHAP 6. BY APPLICATION
6.1. PROFESSIONAL CGMS (FOR HEALTHCARE PROFESSIONALS)
6.1.1. PROFESSIONAL CGMS TYPES
6.1.2. CASE STUDY ON USE OF CGMS IN HOSPITAL SETTINGS
6.1.3. CASE STUDY 2: MEDTRONIC REAL TIME CGMS IN RURAL SETTINGS
6.2. PERSONAL CGMS (FOR PATIENTS)
6.2.1. PERSONAL CGMS SEGMENTED ON THE BASIS OF AGE GROUPS
CHAP 7. COMPETITIVE INTELLIGENCE
7.1. KEY STRATEGIES ENABLING CGMS MARKET TO INCREASE ACCEPTANCE
7.1.1. INNOVATION BECOMES THE KEY INDUSTRY STRATEGY TO OVERCOME COMPETITION
7.1.2. TECHNOLOGY LEVERAGING - KEY FOCUS OF PARTNERSHIPS AND AGREEMENTS AMONG MAX INDUSTRY PLAYERS
7.1.3. PRODUCT LAUNCH- A MAKE OR BREAK MARKETING STRATEGY
7.1.3.1. RECENT PRODUCT LAUNCHES
7.1.4. ACQUISITIONS STILL REMAIN NICHE IN THE CGM MARKET
CHAP 8. MARKET SHARE ANALYSIS
8.1. KEY COMPANY ANALYSIS
8.1.1. DEXCOM
8.1.2. MEDTRONIC
8.1.3. ABBOTT
8.1.4. MARKET SHARE
8.1.5. CONCLUSION
CHAP 9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. UNITED STATES OF AMERICA
9.1.1.1. A DEVELOPED ECONOMY A MAJOR DRIVER FOR BUSINESS
9.1.1.2. AWARENESS IS THE KEY TO CGMS ADOPTION
9.1.1.3. MEDICARE AND REIMBURSEMENTS ARE THE FUTURE DRIVERS
9.1.1.4. HIGH NUMBER OF TYPE 1 DIABETES CASES AND HIGH PREVALENCE RATE OF TYPE 1 DIABETES
9.1.1.5. REGULATION OBSTRUCTING THE MARKET EXPANSION
9.1.1.5.1. US FDA'S GUIDELINES FOR THE DEVELOPMENT OF ARTIFICIAL PANCREAS
9.1.1.5.1.1. PRIMARY COMPONENTS OF AN APD
9.1.1.5.1.2. SECONDARY COMPONENT
9.1.1.6. KEY MARKET PLAYERS IN THE U.S
9.2. CANADA
9.2.1. REGULATIONS IN CANADA
9.3. EUROPE
9.3.1. EUROPEAN UNION
9.3.1.1. UNITED KINGDOM
9.3.1.1.1. REGULATIONS IN UNITED KINGDOM
9.3.1.1.2. KEY COMPANIES IN UNITED KINGDOM
9.3.1.2. FRANCE
9.3.1.3. GERMANY
9.4. ASIA PACIFIC
9.4.1. CHINA:
9.4.1.1. REGULATIONS IN CHINA
9.4.2. INDIA
9.4.2.1. REGULATION IN INDIA
9.4.2.1.1. CGMS IN INDIA
9.4.3. AUSTRALIA
9.4.3.1.1. REGULATIONS IN AUSTRALIA
9.5. LATIN AMERICA
9.5.1. FACTSHEET OF DIABETES STATISTICS IN LATIN AMERICA
9.5.1.1. BRAZIL
9.5.1.2. ARGENTINA
9.5.1.3. MEXICO
9.5.2. REST OF THE WORLD
9.5.2.1. MIDDLE-EAST AND NORTH AFRICA
9.5.2.2. AFRICA
CHAP 10. CORPORATE PROFILE: BENCHMARK STUDY
10.1. MEDTRONIC INC.
10.1.1. LOCATIONS
10.1.2. BUSINESS PROFILE
10.1.3. PRODUCT PORTFOLIO
10.1.4. REVENUE ANALYSIS
10.1.5. STRATEGIC INPUTS
10.2. DEXCOM
10.2.1. LOCATION
10.2.2. BUSINESS PROFILE
10.2.3. PRODUCT PORTFOLIO
10.2.5. STRATEGIC INPUTS
10.3. ABBOTT
10.3.1. LOCATIONS
10.3.2. BUSINESS PROFILE
10.3.3. PRODUCT PORTFOLIO
10.3.4. REVENUE ANALYSIS
10.3.5. STRATEGIC INPUTS
10.4. JOHNSON AND JOHNSON (ANIMAS CORP)
10.4.1. LOCATIONS
10.4.2. BUSINESS PORTFOLIO
10.4.3. PRODUCT PORTFOLIO
10.4.4. REVENUE ANALYSIS
10.5. INSULET CORP
10.5.1. GEOGRAPHY
10.5.2. BUSINESS PORTFOLIO
10.5.3. PRODUCT PORTFOLIO
10.5.4. REVENUE ANALYSIS
10.5.5. STRATEGIC INPUTS
10.6. TANDEM DIABETES
10.7. ECHO THERAPEUTICS

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3065116/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Web Address: http://www.researchandmarkets.com/reports/3065116/
Office Code: SCPL5TTU

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>□</td>
<td>USD 7000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>□</td>
<td>USD 8500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World